Metabolic Research Peptides

Incretin-based research peptides for studies on metabolic regulation, adiposity and glycaemic control. Retatrutide (LY3437943) as the first GLP-1/GIP/glucagon triple agonist with up to 24 percent weight loss in Phase 2 (NEJM 2023) and positive Phase 3 readouts from TRIUMPH-4. Alongside it, AOD-9604 as hGH fragment 177-191 for targeted lipolysis research without systemic incretin activity. Both compounds ship with Janoshik third-party COAs, EU warehouse, DHL premium shipping with a reduced 8-euro rate inside Germany.

Featured in this category

AOD-9604

Modified hGH fragment (177-191) studied for fat metabolism and lipolysis research. Interacts with beta-3 adrenergic receptors without growth-promoting effects.

from €29.99View product →

Retatrutide

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

from €109.99View product →

Cagrilintide

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

from €59.99View product →

All products

-25%

Metabolic

AOD-9604

Modified hGH fragment (177-191) studied for fat metabolism and lipolysis research. Interacts with beta-3 adrenergic receptors without growth-promoting effects.

€29.99

€39.99

-8%

Metabolic

Retatrutide

€109.99

€119.99

-14%

Metabolic

Cagrilintide

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

€59.99

€69.99

Related research

June 25, 2026

Cagrilintide Alone Versus Semaglutide: What the New 2026 Meta-Analysis Actually Shows

A 2026 meta-analysis (Diabetes, Obesity and Metabolism) compares Cagrilintide monotherapy with Semaglutide: comparable weight loss, but a higher signal for serious adverse events. The data put into sober context.

June 25, 2026

Retatrutide in Type 2 Diabetes: What the First Phase 3 Diabetes Trial TRANSCEND-T2D-1 Shows (Lancet, June 2026)

TRANSCEND-T2D-1 is the first Phase 3 trial of Retatrutide in type 2 diabetes. HbA1c down to -2.0 points and up to 15.3% weight loss as monotherapy. The numbers in research context.

June 6, 2026

CagriSema REIMAGINE: First Phase 3 Data at ADA 2026 (Cagrilintide plus Semaglutide)

ADA 2026, New Orleans: Novo Nordisk presents detailed Phase 3 data on REIMAGINE 1, 2, 3 for CagriSema (cagrilintide plus semaglutide).